Bryn Inc.
Officers & Directors
David Lazar, age 34, has served as CEO and Chairman of the Company since July 6, 2023. He is a private investor and partner at Zenith Partners International since 2013, with expertise in research and development, sales, and marketing. Lazar was CEO of Dico, Inc. from 2014 to 2015, which was sold to Peekay Boutiques. Since 2018, he has been managing member of Custodian Ventures LLC and Activist Investing LLC, focusing on distressed public companies. He possesses extensive knowledge in financial, legal, and operations management, public company management, accounting, audit preparation, due diligence, and SEC regulations. Lazar currently serves as Chairman and CEO of Titan Pharmaceuticals, Inc. From 2018 to present, he has held various executive and director roles—including CEO, Chairman, President, CFO, and Secretary—at multiple companies, including Rarus Technologies, Inc., DRS, Inc., Energenx, Inc., Melt, Inc., Nevtah Capital Management Corporation, Mediashift, Inc., Sollensys Corp., ForU Holdings, Inc., Superbox, Inc., Petrone Worldwide, Inc., Gushen, Inc., Reliance Global Group Inc., GHAR, Inc., PhoneBrasil, XXStream Entertainment, 9 Adorbs Inc., China Botanic Pharmaceutical, Inc., C2E Energy Inc., Finotec, 3D Makerjet Inc., Pan Global Corp., Balincan International, Inc., Shengshi Elevator International, Romulus Corp., Momentous Holdings Corp., Minim, Inc., Opgen, Inc., Byrn, Inc., LQR House Inc., NovaBay Pharmaceuticals, Inc., Kala Bio, Inc., Indaptus Therapeutics, Inc., Sow Good Inc., and Mainz Biomed N.V. The Company has no formal employment agreement with Lazar, who is its sole employee, director, and officer. There are no reported family relationships or involvement in certain legal proceedings for the directors or executive officers.
|
|
